Symbols / TELA Stock $0.96 -5.88% TELA Bio, Inc.

Healthcare • Medical Devices • United States • NGM
TELA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Antony Koblish
Exch · Country NGM · United States
Market Cap 42.98M
Enterprise Value 52.44M
Income -38.83M
Sales 80.28M
FCF (ttm) -16.95M
Book/sh 0.14
Cash/sh 1.14
Employees —
Insider 10d —
IPO Nov 08, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.71
PEG —
P/S 0.54
P/B 6.76
P/C —
EV/EBITDA -1.60
EV/Sales 0.65
Quick Ratio 3.40
Current Ratio 4.21
Debt/Eq 913.26
LT Debt/Eq —
EPS (ttm) -0.83
EPS next Y -0.56
EPS Growth —
Revenue Growth 18.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2026-05-12
ROA -25.12%
ROE -223.35%
ROIC —
Gross Margin 68.17%
Oper. Margin -31.86%
Profit Margin -48.37%
Shs Outstand 44.77M
Shs Float 19.47M
Insider Own 8.42%
Instit Own 69.48%
Short Float 2.48%
Short Ratio 4.12
Short Interest 765.76K
52W High 2.20
vs 52W High -56.36%
52W Low 0.50
vs 52W Low 91.62%
Beta 1.30
Impl. Vol. 6.88%
Rel Volume 0.68
Avg Volume 184.37K
Volume 125.47K
Target (mean) $2.25
Tgt Median $2.00
Tgt Low $1.00
Tgt High $3.25
# Analysts 5
Recom Buy
Prev Close $1.02
Price $0.96
Change -5.88%
About

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$2.25
Mean price target
2. Current target
$0.96
Latest analyst target
3. DCF / Fair value
$-6.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.96
Low
$1.00
High
$3.25
Mean
$2.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-27 main Citizens Market Outperform → Market Outperform $3
2026-03-25 main Piper Sandler Neutral → Neutral $1
2026-03-25 main Lake Street Buy → Buy $2
2026-03-25 main Canaccord Genuity Buy → Buy $2
2025-12-01 main Lake Street Buy → Buy $3
2025-11-18 main Canaccord Genuity Buy → Buy $4
2025-11-14 reit Piper Sandler Neutral → Neutral $1
2025-11-14 main Citizens Market Outperform → Market Outperform $5
2025-03-21 main Canaccord Genuity Buy → Buy $7
2025-03-21 main Citizens Capital Markets Market Outperform → Market Outperform $7
2025-03-21 down Piper Sandler Overweight → Neutral $2
2024-11-08 main Piper Sandler Overweight → Overweight $5
2024-10-04 main Canaccord Genuity Buy → Buy $12
2024-08-13 main Lake Street Buy → Buy $8
2024-08-13 main Canaccord Genuity Buy → Buy $12
2024-08-13 main JMP Securities Market Outperform → Market Outperform $12
2024-08-13 main Piper Sandler Overweight → Overweight $8
2024-07-25 main Canaccord Genuity Buy → Buy $14
2024-05-10 reit Piper Sandler Overweight → Overweight $10
2024-03-22 reit JMP Securities Market Outperform → Market Outperform $15
News
RSS: Latest TELA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-20 KOBLISH ANTONY Chief Executive Officer — 176,000 $0.00 $0
2026-02-20 CUCA ROBERTO Chief Operating Officer — 57,000 $0.00 $0
2026-02-20 TALMO PAUL Chief Technology Officer — 57,000 $0.00 $0
2026-02-20 FIRESTONE GREGORY A Officer — 37,000 $0.00 $0
2026-02-20 BLIZARD JEFFREY President — 86,000 $0.00 $0
2026-02-18 SMEYKAL MEGAN Officer — 32,850 $0.00 $0
2025-11-17 EW HEALTHCARE PARTNERS FUND 2, L.P. Beneficial Owner of more than 10% of a Class of Security — 3,604,000 $1.11 $4,000,440
2025-10-31 PLOVANIC WILLIAM J. Director — 11,925 $0.00 $0
2025-10-09 ROCCHIO BETTY JO Director — 11,925 $0.00 $0
2025-06-02 BLIZARD JEFFREY President — 104,800 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
80.28
+15.84%
69.30
+18.56%
58.45
+41.13%
41.42
Operating Revenue
80.28
+15.84%
69.30
+18.56%
58.45
+41.13%
41.42
Cost Of Revenue
25.93
+13.69%
22.81
+24.38%
18.34
+27.60%
14.37
Reconciled Cost Of Revenue
25.93
+13.69%
22.81
+24.38%
18.34
+27.60%
14.37
Gross Profit
54.34
+16.89%
46.49
+15.90%
40.11
+48.32%
27.04
Operating Expense
88.10
-0.10%
88.18
+4.75%
84.19
+27.46%
66.05
Research And Development
9.22
+4.62%
8.81
-8.38%
9.62
+7.63%
8.94
Selling General And Administration
78.88
-0.62%
79.37
+6.44%
74.57
+30.56%
57.11
Selling And Marketing Expense
63.18
-2.27%
64.65
+8.32%
59.68
+37.98%
43.25
General And Administrative Expense
15.69
+6.60%
14.72
-1.11%
14.89
+7.39%
13.86
Other Gand A
15.69
+6.60%
14.72
-1.11%
14.89
+7.39%
13.86
Total Expenses
114.03
+2.73%
111.00
+8.26%
102.53
+27.48%
80.42
Operating Income
-33.76
+19.04%
-41.70
+5.40%
-44.08
-12.99%
-39.01
Total Operating Income As Reported
-33.76
+1.06%
-34.12
+22.60%
-44.08
-12.99%
-39.01
EBITDA
-32.35
-2.09%
-31.68
+22.03%
-40.63
-4.03%
-39.06
Normalized EBITDA
-31.46
+19.88%
-39.26
+3.37%
-40.63
-7.41%
-37.83
Reconciled Depreciation
1.01
-0.20%
1.01
+25.25%
0.81
-31.93%
1.19
EBIT
-33.36
-2.02%
-32.70
+21.10%
-41.44
-2.97%
-40.24
Total Unusual Items
-0.89
-111.72%
7.58
0.00
+100.00%
-1.23
Total Unusual Items Excluding Goodwill
-0.89
-111.72%
7.58
0.00
+100.00%
-1.23
Special Income Charges
-0.89
-111.72%
7.58
0.00
+100.00%
-1.23
Other Special Charges
0.89
—
—
1.23
Net Income
-38.83
-2.62%
-37.84
+18.91%
-46.66
-5.35%
-44.30
Pretax Income
-38.60
-1.62%
-37.98
+18.60%
-46.66
-5.35%
-44.30
Net Non Operating Interest Income Expense
-5.25
+0.85%
-5.29
-1.28%
-5.22
-28.93%
-4.05
Interest Expense Non Operating
5.25
-0.85%
5.29
+1.28%
5.22
+28.93%
4.05
Net Interest Income
-5.25
+0.85%
-5.29
-1.28%
-5.22
-28.93%
-4.05
Interest Expense
5.25
-0.85%
5.29
+1.28%
5.22
+28.93%
4.05
Other Income Expense
0.40
-95.57%
9.00
+241.69%
2.63
+312.76%
-1.24
Other Non Operating Income Expenses
1.29
-9.37%
1.42
-46.09%
2.63
+26440.00%
-0.01
Gain On Sale Of Business
0.00
-100.00%
7.58
0.00
0.00
Tax Provision
0.23
+259.72%
-0.14
0.00
0.00
Tax Rate For Calcs
0.00
+5150.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
-0.19
-715.04%
0.03
0.00
0.00
Net Income Including Noncontrolling Interests
-38.83
-2.62%
-37.84
+18.91%
-46.66
-5.35%
-44.30
Net Income From Continuing Operation Net Minority Interest
-38.83
-2.62%
-37.84
+18.91%
-46.66
-5.35%
-44.30
Net Income From Continuing And Discontinued Operation
-38.83
-2.62%
-37.84
+18.91%
-46.66
-5.35%
-44.30
Net Income Continuous Operations
-38.83
-2.62%
-37.84
+18.91%
-46.66
-5.35%
-44.30
Normalized Income
-38.13
+16.00%
-45.39
+2.73%
-46.66
-8.35%
-43.07
Net Income Common Stockholders
-38.83
-2.62%
-37.84
+18.91%
-46.66
-5.35%
-44.30
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
—
-1.33
+34.80%
-2.04
+25.00%
-2.72
Basic EPS
—
-1.33
+34.80%
-2.04
+25.00%
-2.72
Basic Average Shares
—
28.53
+24.74%
22.87
+40.58%
16.27
Diluted Average Shares
—
28.53
+24.74%
22.87
+40.58%
16.27
Diluted NI Availto Com Stockholders
-38.83
-2.62%
-37.84
+18.91%
-46.66
-5.35%
-44.30
Line Item Trend 2021-12-31
Total Assets
—
Current Assets
—
Cash Cash Equivalents And Short Term Investments
—
Cash And Cash Equivalents
—
Receivables
—
Accounts Receivable
—
Gross Accounts Receivable
—
Allowance For Doubtful Accounts Receivable
—
Inventory
—
Raw Materials
—
Finished Goods
—
Prepaid Assets
3.23
Other Current Assets
—
Total Non Current Assets
—
Net PPE
—
Gross PPE
—
Accumulated Depreciation
—
Properties
—
Machinery Furniture Equipment
—
Other Properties
—
Leases
—
Goodwill And Other Intangible Assets
—
Non Current Deferred Assets
—
Non Current Deferred Taxes Assets
—
Other Non Current Assets
—
Total Liabilities Net Minority Interest
—
Current Liabilities
—
Payables And Accrued Expenses
—
Payables
—
Accounts Payable
—
Current Accrued Expenses
—
Pensionand Other Post Retirement Benefit Plans Current
—
Total Tax Payable
—
Income Tax Payable
—
Current Debt And Capital Lease Obligation
—
Current Capital Lease Obligation
—
Other Current Liabilities
0.08
Total Non Current Liabilities Net Minority Interest
—
Long Term Debt And Capital Lease Obligation
—
Long Term Debt
—
Other Non Current Liabilities
—
Stockholders Equity
—
Common Stock Equity
—
Capital Stock
—
Common Stock
—
Preferred Stock
—
Share Issued
—
Ordinary Shares Number
—
Treasury Shares Number
0.00
Additional Paid In Capital
—
Retained Earnings
—
Gains Losses Not Affecting Retained Earnings
—
Other Equity Adjustments
—
Total Equity Gross Minority Interest
—
Total Capitalization
—
Working Capital
—
Invested Capital
—
Total Debt
—
Net Debt
—
Capital Lease Obligations
—
Net Tangible Assets
—
Tangible Book Value
—
Dueto Related Parties Current
—
Interest Payable
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-28.22
+32.16%
-41.59
-1.81%
-40.86
-0.27%
-40.75
Cash Flow From Continuing Operating Activities
-28.22
+32.16%
-41.59
-1.81%
-40.86
-0.27%
-40.75
Net Income From Continuing Operations
-38.83
-2.62%
-37.84
+18.91%
-46.66
-5.35%
-44.30
Depreciation Amortization Depletion
1.01
-0.20%
1.01
+25.25%
0.81
-31.93%
1.19
Depreciation
0.63
-0.32%
0.63
+47.66%
0.43
+11.75%
0.38
Amortization Cash Flow
0.38
+0.00%
0.38
+0.00%
0.38
-52.74%
0.80
Depreciation And Amortization
1.01
-0.20%
1.01
+25.25%
0.81
-31.93%
1.19
Amortization Of Intangibles
0.38
+0.00%
0.38
+0.00%
0.38
-52.74%
0.80
Other Non Cash Items
3.27
-4.75%
3.43
+108.13%
1.65
-43.31%
2.91
Stock Based Compensation
3.80
-12.98%
4.36
-13.31%
5.03
+26.15%
3.99
Deferred Tax
0.23
+259.72%
-0.14
0.00
0.00
Deferred Income Tax
0.23
+259.72%
-0.14
0.00
0.00
Operating Gains Losses
0.89
+111.72%
-7.58
-63066.67%
-0.01
-100.98%
1.23
Net Foreign Currency Exchange Gain Loss
—
—
-0.32
-175.24%
0.42
Gain Loss On Sale Of PPE
0.00
0.00
+100.00%
-0.01
0.00
Change In Working Capital
1.42
+129.40%
-4.83
-189.63%
-1.67
+71.04%
-5.76
Change In Receivables
-0.11
+85.56%
-0.76
+75.08%
-3.06
-26.31%
-2.42
Changes In Account Receivables
-0.11
+85.56%
-0.76
+75.08%
-3.06
-26.31%
-2.42
Change In Inventory
-0.50
+83.08%
-2.97
-9.35%
-2.72
+55.24%
-6.07
Change In Prepaid Assets
0.13
-41.41%
0.23
+380.25%
-0.08
-106.66%
1.22
Change In Payables And Accrued Expense
1.90
+243.26%
-1.33
-131.69%
4.19
+176.44%
1.51
Change In Accrued Expense
1.76
+197.29%
-1.81
-143.31%
4.18
+74.11%
2.40
Change In Payable
0.14
-70.75%
0.48
+4281.82%
0.01
+101.24%
-0.88
Change In Account Payable
0.14
-70.75%
0.48
+4281.82%
0.01
+101.24%
-0.88
Investing Cash Flow
0.85
-80.99%
4.45
+843.07%
-0.60
+68.00%
-1.87
Cash Flow From Continuing Investing Activities
0.85
-80.99%
4.45
+843.07%
-0.60
+68.00%
-1.87
Net PPE Purchase And Sale
-0.45
+54.70%
-0.99
-65.11%
-0.60
+31.31%
-0.87
Purchase Of PPE
-0.45
+54.70%
-0.99
-61.87%
-0.61
+29.93%
-0.87
Sale Of PPE
0.00
0.00
-100.00%
0.01
0.00
Capital Expenditure
-0.45
+54.70%
-0.99
-61.87%
-0.61
+67.36%
-1.87
Net Investment Purchase And Sale
—
—
—
0.00
Purchase Of Investment
—
—
—
—
Sale Of Investment
—
—
—
0.00
Net Intangibles Purchase And Sale
—
0.00
0.00
+100.00%
-1.00
Purchase Of Intangibles
—
0.00
0.00
+100.00%
-1.00
Net Other Investing Changes
1.29
-76.21%
5.44
—
—
Financing Cash Flow
25.75
-40.20%
43.06
-6.94%
46.27
+13.26%
40.85
Cash Flow From Continuing Financing Activities
25.75
-40.20%
43.06
-6.94%
46.27
+13.26%
40.85
Net Issuance Payments Of Debt
17.58
0.00
0.00
-100.00%
10.00
Issuance Of Debt
60.00
0.00
0.00
-100.00%
40.00
Repayment Of Debt
-42.42
0.00
0.00
+100.00%
-30.00
Long Term Debt Issuance
60.00
0.00
0.00
-100.00%
40.00
Long Term Debt Payments
-42.42
0.00
0.00
+100.00%
-30.00
Net Long Term Debt Issuance
17.58
0.00
0.00
-100.00%
10.00
Net Common Stock Issuance
11.82
-72.45%
42.92
-7.38%
46.34
+34.71%
34.40
Proceeds From Stock Option Exercised
0.11
-79.09%
0.51
+135.81%
0.21
+211.59%
0.07
Net Other Financing Charges
-3.76
-918.70%
-0.37
-27.68%
-0.29
+92.01%
-3.62
Changes In Cash
-1.62
-127.45%
5.91
+22.91%
4.81
+372.12%
-1.77
Effect Of Exchange Rate Changes
-0.22
-875.00%
0.03
-82.93%
0.16
+213.89%
-0.14
Beginning Cash Position
52.94
+12.64%
46.99
+11.84%
42.02
-4.35%
43.93
End Cash Position
51.09
-3.48%
52.94
+12.64%
46.99
+11.84%
42.02
Free Cash Flow
-28.67
+32.68%
-42.58
-2.69%
-41.47
+2.70%
-42.62
Interest Paid Supplemental Data
4.72
+15.84%
4.07
-11.96%
4.62
+36.24%
3.39
Common Stock Issuance
11.82
-72.45%
42.92
-7.38%
46.34
+34.71%
34.40
Issuance Of Capital Stock
11.82
-72.45%
42.92
-7.38%
46.34
+34.71%
34.40
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category